A prospective study led by researchers from the University of California, San Diego School of Medicine has found that low serum vitamin D levels in the months preceding diagnosis may predict a high risk of premenopausal breast cancer.
It’s that time of year again: flu season. The epidemic this year is widespread, afflicting millions in every state across the country. This year’s flu strain has been reported as particularly virulent, but there are essential steps that the UC San Diego community is encouraged to take to prevent contracting and spreading the flu.
New research from the University of California, San Diego published in the Jan. 23 issue of Science Translational Medicine moves researchers closer to understanding and developing treatments for shock, sepsis and multiorgan failure. Collectively, these maladies represent a major unmet medical need: they are the number one cause of mortality in intensive care units in the United States, with hundreds of thousands of deaths annually. There is currently no treatment for these conditions in spite of many clinical trials.
The University of California, San Diego’s 16th annual Heart of San Diego Gala will honor local philanthropist and community leader Audrey Geisel Feb. 9 at the Grand Hyatt Aviara Resort. The formal fete will include dinner, dancing and a silent auction. Former San Diego Charger Rolf Benirschke will serve as the evening’s emcee. All proceeds from the event will benefit the UC San Diego Sulpizio Cardiovascular Center.
The University of California, San Diego has received a record 82,340 freshman and transfer applications for fall 2013. The university received the third highest number of applicants among the University of California campuses. In recent years, UC San Diego has been among the nation’s top five universities with the most applications.
Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive – and thus vulnerable – to a novel cancer stem cell-targeting drug currently under development.
Keep up with all the latest from UC San Diego. Subscribe to the newsletter today.
